492 related articles for article (PubMed ID: 37467180)
1. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Zacharias HD; Kamel F; Tan J; Kimer N; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011585. PubMed ID: 37467180
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
3. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
[TBL] [Abstract][Full Text] [Related]
4. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
[TBL] [Abstract][Full Text] [Related]
5. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
6. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
7. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.
Colli A; Fraquelli M; Prati D; Casazza G
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013532. PubMed ID: 37278488
[TBL] [Abstract][Full Text] [Related]
9. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-L-carnitine for patients with hepatic encephalopathy.
Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD011451. PubMed ID: 30610762
[TBL] [Abstract][Full Text] [Related]
12. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
[TBL] [Abstract][Full Text] [Related]
13. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD002798. PubMed ID: 28796283
[TBL] [Abstract][Full Text] [Related]
14. Probiotics for people with hepatic encephalopathy.
Dalal R; McGee RG; Riordan SM; Webster AC
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008716. PubMed ID: 28230908
[TBL] [Abstract][Full Text] [Related]
15. Probiotics for patients with hepatic encephalopathy.
McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
[TBL] [Abstract][Full Text] [Related]
16. Colchicine for the treatment of COVID-19.
Mikolajewska A; Fischer AL; Piechotta V; Mueller A; Metzendorf MI; Becker M; Dorando E; Pacheco RL; Martimbianco ALC; Riera R; Skoetz N; Stegemann M
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD015045. PubMed ID: 34658014
[TBL] [Abstract][Full Text] [Related]
17. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis.
Simonetti RG; Perricone G; Nikolova D; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD004039. PubMed ID: 31251387
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic prophylaxis for leptospirosis.
Win TZ; Perinpanathan T; Mukadi P; Smith C; Edwards T; Han SM; Maung HT; Brett-Major DM; Lee N
Cochrane Database Syst Rev; 2024 Mar; 3(3):CD014959. PubMed ID: 38483067
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet agents for the treatment of deep venous thrombosis.
Flumignan CD; Nakano LC; Baptista-Silva JC; Flumignan RL
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012369. PubMed ID: 35876829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]